Advertisement

Novel Cytotoxic Agents in Combination with Radiation in the Management of Locally Advanced Non-Small Cell Lung Cancer: Focus on Pemetrexed and Nab-Paclitaxel [Abraxane]

  • Corey J. Langer
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

The treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) remains challenging. Radiation therapy (RT) combined with chemotherapy is more effective than RT alone, and concomitant chemoradiation has yielded improved survival compared to sequential chemotherapy and RT, but at the cost of heightened toxicity, especially esophagitis. The majority of randomized chemoradiation trials have featured cisplatin or carboplatin based chemotherapy, usually in combination with either etoposide or paclitaxel, with median survival times of 16–18 months, and 5 year survival rates of 15 to 20% at best. In this chapter, we describe recent studies employing pemetrexed and nab-paclitaxel, each of which has been extensively investigated in advanced disease, the former yielding improved progression-free and overall survival in adenocarcinoma both in the frontline and maintenance setting, the latter yielding superior response rates in squamous cell carcinoma compared to conventional paclitaxel in chemo-naïve patients. Both agents have demonstrated safety and efficacy in LA-NSCLC in conjunction with RT. Whether these agents will ever prove superior to either etoposide or paclitaxel in this setting will require careful, phase III testing.

Keywords

Advanced NSCLC Overall Response Rate Thoracic Radiation Anal Canal Cancer Nonsquamous NSCLC 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. ABI 007. Drugs RD (2004) 5:155–159 (For more details see doi: 10.1200/JCO.2005.03.7135
  2. Aupérin A, Rolland E, Curran WJ et al (2007) Concomitant radio-chemotherapy (RT-CT) versus sequential RT–CT in locally advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs): A1-04. J Thorac Oncol 2:S310CrossRefGoogle Scholar
  3. Brade A, Bezjak A, MacRae R (2011) Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small cell lung cancer. Int J Radiat Oncol Biol Phys 79(5):1395–1401 [Epub 2010 Jun 3]PubMedCrossRefGoogle Scholar
  4. Choy H, Curran WJ, Scott CB , Bonomi P, Travis P, Haluschak J, Belani CP (2002) Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 21Google Scholar
  5. Choy H, Schwartzberg LS, Dakhil SR (2010) Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update. J Clin Oncol 28:15s [suppl; abstr 7082]Google Scholar
  6. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440 [Epub 2009 Sep 18. PMID: 19767093]PubMedCrossRefGoogle Scholar
  7. Curran W, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Russell A, Byhardt R, Machtay M, Sause W, Cox JD (2010) Phase III Comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III non-small cell lung cancer (NSCLC): report of radiation therapy oncology group (RTOG) 9410. JNCI (in press)Google Scholar
  8. Damascelli B, Cantu G, Mattavelli F et al (2001) Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92:2592–2602PubMedCrossRefGoogle Scholar
  9. Desai N, Trieu V, Yao Z et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albuminbound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324PubMedCrossRefGoogle Scholar
  10. Furuse K et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17(9):2692–2699PubMedGoogle Scholar
  11. Green MR, Manikhas GM, Orlov S et al (2006) Abraxane(R), a novel Cremophor(R)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer. Ann Oncol 17:126–138CrossRefGoogle Scholar
  12. Govindan R, Bogart J, Wang X et al (2009) Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. Program and abstracts of the 45th annual meeting of the American Society of Clinical Oncology, May 29–June 2, Orlando, Florida, Abstract 7505Google Scholar
  13. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compare with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803PubMedCrossRefGoogle Scholar
  14. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597Google Scholar
  15. Hariri G, Yan H, Wang H, Han Z, Hallahan DE (2010) Radiation-guided drug delivery to mouse models of lung cancer. Clin Cancer Res 16(20):4968–4977 [Epub 2010 Aug 27]PubMedCrossRefGoogle Scholar
  16. Ibrahim NK, Desai N, Legha S et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044PubMedGoogle Scholar
  17. Ibrahim NK, Samuels B, Page R et al (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel in women with metastatic breast cancer. J Clin Oncol 23:6019–6026PubMedCrossRefGoogle Scholar
  18. Movsas B, Scott C, Langer C et al (2005) Randomized trial of amifostine in locally advanced non-small cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23(10):2145–2154PubMedCrossRefGoogle Scholar
  19. Nyman DW, Campbell KJ, Hersh E et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785–7793PubMedCrossRefGoogle Scholar
  20. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26:3543–3551PubMedCrossRefGoogle Scholar
  21. Seiwert TY, Connell PP, Mauer AM et al (2007) A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 13:515–522PubMedCrossRefGoogle Scholar
  22. Socinski MA, Bondarenko IN, Karaseva NA (2010) Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 28:18s [suppl; abstr LBA7511]Google Scholar
  23. Sparreboom A, Baker SD, Verweij J (2005) Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? J Clin Oncol 23:7765–7767PubMedCrossRefGoogle Scholar
  24. Wiedenmann N, Valdecanas D, Hunter N et al (2007) Radiocurability and therapeutic gain 130-nm albumin-bound paclitaxel enhances tumor. Clin Cancer Res 13:1868–1874PubMedCrossRefGoogle Scholar
  25. Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M (2010) Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28(23):3739–3745 Epub 2010 Jul 12PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg  2011

Authors and Affiliations

  1. 1.Abramson Cancer CenterUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations